STTK

MKT CAP:$368M

Shattuck Labs, Inc.

Market Cap

$368M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$7.65+$3.94 (+106.20%)

Apr 23, 2026

Company Details

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical tria...

CEO

Taylor H. Schreiber

IPO Date

Oct 9, 2020

Website

www.shattucklabs.com

Key Metrics TTM

Revenue

$1M

-82.5% YoY

Net Income

-$49M

EPS (Diluted)

-$0.77

Free Cash Flow

-$40M

Revenue / Share

$0.01

Gross Margin

-177.1%

Operating Margin

-5142.7%

Net Margin

-4880.9%

FCF Margin

-3995.3%

P/S

368.4x

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Mar 5, 2026

$1M-82.5%EPS -$0.70

Q4 2025

Mar 5, 2026

$0EPS -$0.12

Q3 2025

Nov 6, 2025

$1M-66.6%EPS -$0.14

Q2 2025

Aug 14, 2025

$0-100.0%EPS -$0.24

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$24M
Q2 22	$50.0K	-$23M	-$28M
Q3 22	$212.0K	-$19M	-$25M
Q4 22	$390.0K	-$21M	-$26M
Q1 23	$57.0K	-$17M	-$22M
Q2 23	$200.0K	-$18M	-$23M
Q3 23	$686.0K	-$24M	-$29M
Q4 23	$714.0K	-$267.0K	-$19M
Q1 24	$1M	$141.0K	-$20M
Q2 24	$2M	$647.0K	-$23M
Q3 24	$3M	$2M	-$18M
Q4 24	$0	$0	-$20M
Q1 25	$0	-$936.0K	-$14M
Q2 25	$0	-$929.0K	-$13M
Q3 25	$1M	$1M	-$11M
Q4 25	$0	-$906.0K	-$13M

Valuation

Quarter	P/S	P/E
Q1 22	13.3x	—
Q2 22	11.5x	—
Q3 22	12.1x	—
Q4 22	565.0x	—
Q1 23	519.6x	—
Q2 23	428.8x	—
Q3 23	276.4x	—
Q4 23	222.3x	—
Q1 24	135.7x	—
Q2 24	89.3x	—
Q3 24	57.2x	—
Q4 24	64.4x	—
Q1 25	80.0x	—
Q2 25	122.9x	—
Q3 25	368.4x	—
Q4 25	368.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$26M	-$29M
Q2 22	-$16M	-$24M
Q3 22	-$28M	-$29M
Q4 22	-$24M	-$25M
Q1 23	-$26M	-$27M
Q2 23	-$19M	-$19M
Q3 23	-$17M	-$17M
Q4 23	-$19M	-$19M
Q1 24	-$16M	-$16M
Q2 24	-$11M	-$11M
Q3 24	-$16M	-$16M
Q4 24	-$17M	-$17M
Q1 25	-$12M	-$12M
Q2 25	-$10M	-$10M
Q3 25	-$9M	-$9M
Q4 25	-$8M	-$8M

Capital Expenditures

Quarter	CapEx
Q1 22	$2M
Q2 22	$8M
Q3 22	$750.0K
Q4 22	$693.0K
Q1 23	$75.0K
Q2 23	$296.0K
Q3 23	$19.0K
Q4 23	$17.0K
Q1 24	$0
Q2 24	$17.0K
Q3 24	$42.0K
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$71.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-100.0%	+64.5%
Q2 22	+101.2%	+36.6%
Q3 22	-88.8%	+30.6%
Q4 22	-98.7%	+28.0%
Q1 23	—	-10.1%
Q2 23	+300.0%	-17.2%
Q3 23	+223.6%	+15.1%
Q4 23	+83.1%	-26.3%
Q1 24	+1856.1%	-2.6%
Q2 24	+704.5%	+7.1%
Q3 24	+336.9%	-28.6%
Q4 24	-100.0%	-0.1%
Q1 25	-100.0%	-32.0%
Q2 25	-100.0%	-47.0%
Q3 25	-66.6%	-44.0%
Q4 25	—	-32.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$2M	3066.0%
Q3 22	$2M	812.7%
Q4 22	$2M	434.1%
Q1 23	$0	0.0%
Q2 23	$2M	926.0%
Q3 23	$2M	257.1%
Q4 23	$2M	229.7%
Q1 24	$2M	222.0%
Q2 24	$3M	165.6%
Q3 24	$3M	85.3%
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$0	0.0%
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$19M	$5M	—
Q2 22	$23M	$5M	—
Q3 22	$19M	$7M	—
Q4 22	$22M	$3M	—
Q1 23	$17M	$5M	—
Q2 23	$18M	$5M	—
Q3 23	$24M	$5M	—
Q4 23	$15M	$4M	—
Q1 24	$16M	$5M	—
Q2 24	$19M	$5M	—
Q3 24	$16M	$5M	—
Q4 24	$15M	$4M	—
Q1 25	$10M	$4M	—
Q2 25	$9M	$4M	—
Q3 25	$8M	$4M	—
Q4 25	$8M	—	$4M

Revenue Segments

Quarter	License
Q3 24	$3M
Q3 25	$1M
Q4 25	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$51M	$188M	$239M
Q2 22	$38M	$176M	$214M
Q3 22	$40M	$145M	$185M
Q4 22	$47M	$114M	$161M
Q1 23	$66M	$69M	$135M
Q2 23	$72M	$45M	$117M
Q3 23	$41M	$60M	$101M
Q4 23	$126M	$5M	$131M
Q1 24	$76M	$39M	$115M
Q2 24	$61M	$45M	$105M
Q3 24	$44M	$46M	$90M
Q4 24	$57M	$16M	$73M
Q1 25	$61M	$0	$61M
Q2 25	$50M	$0	$50M
Q3 25	$43M	$0	$43M
Q4 25	$54M	$24M	$78M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	42M	-5.3%	+1.4%
Q2 22	42M	+0.1%	+1.1%
Q3 22	42M	+0.0%	+0.5%
Q4 22	42M	+0.0%	-5.2%
Q1 23	42M	+0.1%	+0.2%
Q2 23	42M	+0.1%	+0.2%
Q3 23	42M	+0.0%	+0.2%
Q4 23	43M	+1.3%	+1.5%
Q1 24	51M	+17.6%	+19.2%
Q2 24	51M	+0.4%	+19.6%
Q3 24	51M	+0.1%	+19.7%
Q4 24	51M	+0.0%	+18.2%
Q1 25	51M	+0.2%	+0.8%
Q2 25	51M	+0.1%	+0.4%
Q3 25	72M	+41.5%	+42.0%
Q4 25	104M	+43.8%	+104.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	85
Q2 22	$588	85
Q3 22	$2.5K	85
Q4 22	$3.7K	105
Q1 23	$543	105
Q2 23	$1.9K	105
Q3 23	$6.5K	105
Q4 23	$9.5K	75
Q1 24	$14.9K	75
Q2 24	$21.5K	75
Q3 24	$40.0K	75
Q4 24	$0	44
Q1 25	$0	44
Q2 25	$0	44
Q3 25	$22.7K	44
Q4 25	$0	200K

Revenue / Employee